查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1856929

感染疾病控制市场预测至2032年：按产品、类型、最终用户和地区分類的全球分析

Infectious Disease Management Market Forecasts to 2032 - Global Analysis By Product (Diagnostics, Therapeutics, Vaccines), Type, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，预计 2025 年全球感染疾病控制市场规模将达到 233 亿美元，到 2032 年将达到 389 亿美元，预测期内复合年增长率为 7.6%。

感染疾病防治是指对由细菌、病毒、真菌和寄生虫等病原体引起的疾病进行预防、诊断、治疗和管理的综合方法。它包括监测、利用诊断工具进行早期检测、及时医疗干预以及限制传播的公共卫生策略。疫苗接种计划、抗菌治疗和隔离措施是重要的组成部分。有效的防治还包括教育、卫生管理以及为因应疫情爆发和疫情而进行的全球合作。生物技术和数据分析的进步使感染疾病防治更加积极主动，使医疗卫生系统能够快速回应并减少疫情对人群的影响。

全球感染风险日益增加

全球感染疾病的日益增加是推动市场发展的主要因素。新冠病毒、流感以及新兴病原体等病毒的频繁爆发提高了全球的防控意识，并提升了对健全的疾病防治体系的需求。各国政府和医疗机构正在增加对监测、诊断和治疗基础设施的投入，以降低风险。这种对感染疾病防治日益增长的迫切性正在刺激市场创新和扩张，使感染疾病防治成为各地区的首要任务。

先进诊断工具高成本

先进诊断工具的高昂成本是限制市场成长的主要因素。分子检测、基因定序和快速诊断等技术需要对设备、培训和维护进行大量投资。这些成本对于中低收入国家的医疗卫生系统而言可能难以承受，从而限制了及时、准确疾病检测的普及。因此，医疗基础设施的差异和经济负担阻碍了有效感染疾病控制方案的广泛应用，减缓了市场渗透率。

诊断技术的进步

诊断技术的进步为市场带来了广泛的机会。即时检测、人工智慧主导的分析以及携带式诊断设备等创新技术能够快速且准确地检测病原体。这些工具透过促进早期疗育和减少感染，改善了患者的治疗效果。随着医疗系统拥抱数位转型和个人化医疗，对尖端诊断技术的需求持续成长。预计这一趋势将推动市场显着成长，并重塑感染疾病管理格局。

监管障碍

监管障碍对市场构成显着威胁。新诊断试剂、治疗药物和疫苗的严格核准流程可能会延迟产品上市，并在疫情爆发期间限制其使用。遵守各项国际标准也为製造商和医疗服务提供者带来了复杂性。这些挑战会减缓创新步伐，并阻碍对新出现的健康威胁做出及时反应。透过简化政策和加强全球合作来解决监管瓶颈，对于快速部署有效的疾病控制方案至关重要。

新冠疫情的影响：

新冠疫情对感染疾病防治市场产生了重大影响，加速了对诊断、疫苗和治疗方案的需求。疫情暴露了全球医疗基础设施的不足，凸显了快速反应系统的必要性。各国政府和组织在研究、检测和公共卫生领域投入巨资，推动了创新与合作。疫情也促进了数位医疗技术和远端医疗的应用。儘管疫情扰乱了供应链并加剧了资源紧张，但最终也透过持续的改进重塑了市场格局。

预计疫苗板块在预测期内将成为最大的板块。

预计在预测期内，疫苗领域将占据最大的市场份额，因为疫苗在预防感染疾病传播和减轻医疗负担方面发挥关键作用。新冠肺炎疫苗宣传活动的成功凸显了疫苗的重要性，促使相关领域的投资和研发不断增加。 mRNA技术的进步、全球疫苗接种计划以及公众意识的提高都推动了该领域的成长。随着新病原体的出现，疫苗仍然是主动疾病控制和公共卫生策略的基石。

预计真菌感染疾病细分市场在预测期内将实现最高的复合年增长率。

由于真菌疾病病例不断增加，尤其是在免疫力人群中，对专业诊断和治疗的需求日益增长，预计真菌感染疾病市场在预测期内将呈现最高的增长率。气候变迁、抗生素抗药性和住院率上升是导致真菌感染疾病盛行率上升的原因。抗真菌疗法的创新和检测方法的改进正在改善患者的治疗效果。随着人们对真菌感染疾病的认识不断提高以及相关研究的深入，真菌感染疾病管理市场预计将快速成长，超过其他细分市场。

比最大的地区

预计亚太地区将在预测期内占据最大的市场份额。该地区人口密度高、疫情频繁爆发以及不断完善的医疗基础设施，推动了对有效疾病控制解决方案的需求。中国、印度和日本等国家正在加大对诊断、疫苗接种计画和公共卫生措施的投入。政府支持、公众意识的提高以及技术的应用，进一步推动了市场成长。亚太地区对感染疾病控制的策略重视，使其在全球市场中占据了有利地位。

复合年增长率最高的地区：

预计北美地区在预测期内将实现最高的复合年增长率，这得益于该地区强大的医疗基础设施、先进的研究能力和积极的公共卫生政策，这些都为快速的技术创新提供了支持。对个人化医疗、数位诊断和疫苗研发的强劲需求将推动市场成长。对生物技术的投资以及政府与私营部门之间的合作正在促进市场扩张。北美在技术进步和疾病监测方面持续保持领先地位，从而推动了感染疾病控制市场的蓬勃发展。

免费客製化服务：

订阅本报告的用户可享有以下免费客製化服务之一：

  • 公司简介
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行市场估算、预测和复合年增长率分析（註：基于可行性检查）
  • 竞争基准化分析
    • 基于产品系列、地域覆盖和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 原始研究资料
    • 次级研究资讯来源
    • 先决条件

第三章 市场趋势分析

  • 司机
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 终端用户分析
  • 新兴市场
  • 新冠疫情的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球感染疾病控制市场（依产品划分）

  • 诊断
    • PCR和分子诊断
    • 免疫检测
    • 快速检测套组
  • 治疗药物
    • 抗生素
    • 抗病毒药物
    • 抗真菌药物
    • 抗寄生虫药物
  • 疫苗
    • 病毒疫苗
    • 细菌疫苗

6. 全球感染疾病控制市场（按类型划分）

  • 细菌感染疾病
    • 结核
    • 肺炎
  • 病毒感染
    • 爱滋病毒/爱滋病
    • 流感
    • 肝炎
    • COVID-19
  • 霉菌感染疾病
  • 寄生虫感染疾病

7. 全球感染疾病控制市场（依最终用户划分）

  • 医院
  • 诊断实验室
  • 门诊治疗中心
  • 研究和学术机构
  • 家庭医疗保健
  • 数位健康解决方案
  • 其他最终用户

8. 全球感染疾病控制市场（按地区划分）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 亚太其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲国家
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第九章：重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与併购
  • 新产品上市
  • 业务拓展
  • 其他关键策略

第十章：企业概况

  • Pfizer
  • Gilead Sciences
  • Johnson & Johnson
  • Merck & Co.
  • GlaxoSmithKline（GSK）
  • Roche
  • Sanofi
  • Novartis
  • AstraZeneca
  • AbbVie
  • Takeda Pharmaceutical
  • BioNTech
  • Moderna
  • Eli Lilly and Company
  • Bayer AG
Product Code: SMRC31793

According to Stratistics MRC, the Global Infectious Disease Management Market is accounted for $23.3 billion in 2025 and is expected to reach $38.9 billion by 2032 growing at a CAGR of 7.6% during the forecast period. Infectious disease management refers to the comprehensive approach used to prevent, diagnose, treat, and control diseases caused by pathogens such as bacteria, viruses, fungi, and parasites. It involves surveillance, early detection through diagnostic tools, timely medical intervention, and public health strategies to limit transmission. Vaccination programs, antimicrobial therapies, and quarantine measures are key components. Effective management also includes education, sanitation, and global collaboration to address outbreaks and pandemics. With advancements in biotechnology and data analytics, infectious disease management has become more proactive, enabling healthcare systems to respond swiftly and reduce the impact of contagious illnesses on populations.

Market Dynamics:

Driver:

Rising global infectious risks

The increasing prevalence of infectious diseases worldwide is a major driver of the market. Frequent outbreaks of viruses like COVID-19, influenza, and emerging pathogens have heightened global awareness and demand for robust disease control systems. Governments and healthcare providers are investing in surveillance, diagnostics, and treatment infrastructure to mitigate risks. This growing urgency to contain and prevent infections is fueling innovation and expansion in the market, making infectious disease management a top priority across regions.

Restraint:

High cost of advanced diagnostics

The high cost of advanced diagnostic tools poses a significant restraint to market growth. Technologies such as molecular testing, genomic sequencing, and rapid diagnostics require substantial investment in equipment, training, and maintenance. These expenses can be prohibitive for healthcare systems in low- and middle-income countries, limiting access to timely and accurate disease detection. As a result, disparities in healthcare infrastructure and affordability hinder the widespread adoption of effective infectious disease management solutions, slowing market penetration.

Opportunity:

Advancements in diagnostics

Technological advancements in diagnostics offer a promising opportunity for the market. Innovations like point-of-care testing, AI-driven analysis and portable diagnostic devices enable faster, more accurate detection of pathogens. These tools improve patient outcomes by facilitating early intervention and reducing transmission. As healthcare systems embrace digital transformation and personalized medicine, the demand for cutting-edge diagnostics continues to rise. This trend is expected to drive significant growth and reshape the landscape of infectious disease management.

Threat:

Regulatory hurdles

Regulatory hurdles present a notable threat to the market. Stringent approval processes for new diagnostics, treatments, and vaccines can delay product launches and limit access during critical outbreaks. Compliance with varying international standards adds complexity for manufacturers and healthcare providers. These challenges may slow innovation and hinder timely responses to emerging health threats. Addressing regulatory bottlenecks through streamlined policies and global collaboration is essential to ensure rapid deployment of effective disease management solutions.

Covid-19 Impact:

The Covid-19 pandemic had a profound impact on the infectious disease management market, accelerating demand for diagnostics, vaccines, and treatment solutions. It exposed gaps in global healthcare infrastructure and emphasized the need for rapid response systems. Governments and organizations invested heavily in research, testing, and public health initiatives, driving innovation and collaboration. The pandemic also spurred adoption of digital health technologies and telemedicine. While it disrupted supply chains and strained resources, Covid-19 ultimately reshaped the market with lasting improvements.

The vaccines segment is expected to be the largest during the forecast period

The vaccines segment is expected to account for the largest market share during the forecast period because Vaccines play a crucial role in preventing the spread of infectious diseases and reducing healthcare burdens. The success of COVID-19 vaccination campaigns has reinforced their importance, prompting increased investment and development. Advances in mRNA technology, global immunization programs, and rising public awareness contribute to the segment's growth. As new pathogens emerge, vaccines remain a cornerstone of proactive disease management and public health strategy.

The fungal infections segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the fungal infections segment is predicted to witness the highest growth rate, due to rising cases of fungal diseases, particularly among immune compromised individuals, are driving demand for specialized diagnostics and treatments. Climate change, antibiotic resistance, and increased hospitalizations contribute to the growing prevalence of fungal infections. Innovations in antifungal therapies and improved detection methods are enhancing patient care. As awareness and research expand, the market for managing fungal infections is expected to grow rapidly, outpacing other segments.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to region's dense population, frequent outbreaks, and expanding healthcare infrastructure drive demand for effective disease control solutions. Countries like China, India, and Japan are investing in diagnostics, vaccination programs, and public health initiatives. Government support, rising awareness, and technological adoption further boost market growth. Asia Pacific's strategic focus on infectious disease preparedness positions it as a dominant force in the global market.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to region's strong healthcare infrastructure, advanced research capabilities, and proactive public health policies support rapid innovation. High demand for personalized medicine, digital diagnostics, and vaccine development fuels growth. Investments in biotechnology and collaborations between government and private sectors enhance market expansion. As North America continues to lead in technological advancements and disease surveillance, its infectious disease management market is set to surge.

Key players in the market

Some of the key players in Infectious Disease Management Market include Pfizer, Gilead Sciences, Johnson & Johnson, Merck & Co., GlaxoSmithKline (GSK), Roche, Sanofi, Novartis, AstraZeneca, AbbVie, Takeda Pharmaceutical, BioNTech, Moderna, Eli Lilly and Company and Bayer AG.

Key Developments:

In March 2025, Harbour BioMed and AstraZeneca have embarked on a global collaboration to discover and develop next-generation multi-specific antibodies targeting immunology, oncology, and other therapeutic areas.

In March 2025, Bayer and Neste entered a strategic partnership to develop winter canola as a sustainable feedstock for renewable fuels. This collaboration aims to establish a U.S.-based winter canola ecosystem, enhancing soil health and carbon sequestration.

Products Covered:

  • Diagnostics
  • Therapeutics
  • Vaccines

Types Covered:

  • Bacterial Infections
  • Viral Infections
  • Fungal Infections
  • Parasitic Infections

End Users Covered:

  • Hospitals
  • Diagnostic Laboratories
  • Ambulatory Care Centers
  • Research & Academic Institutes
  • Home Healthcare
  • Digital Health Solutions
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Infectious Disease Management Market, By Product

  • 5.1 Introduction
  • 5.2 Diagnostics
    • 5.2.1 PCR & Molecular Diagnostics
    • 5.2.2 Immunoassays
    • 5.2.3 Rapid Test Kits
  • 5.3 Therapeutics
    • 5.3.1 Antibiotics
    • 5.3.2 Antivirals
    • 5.3.3 Antifungals
    • 5.3.4 Antiparasitic Drugs
  • 5.4 Vaccines
    • 5.4.1 Viral Vaccines
    • 5.4.2 Bacterial Vaccines

6 Global Infectious Disease Management Market, By Type

  • 6.1 Introduction
  • 6.2 Bacterial Infections
    • 5.2.1 Tuberculosis
    • 5.2.2 Pneumonia
  • 6.3 Viral Infections
    • 5.3.1 HIV/AIDS
    • 5.3.2 Influenza
    • 5.3.3 Hepatitis
    • 5.3.4 COVID-19
  • 6.4 Fungal Infections
  • 6.5 Parasitic Infections

7 Global Infectious Disease Management Market, By End User

  • 7.1 Introduction
  • 7.2 Hospitals
  • 7.3 Diagnostic Laboratories
  • 7.4 Ambulatory Care Centers
  • 7.5 Research & Academic Institutes
  • 7.6 Home Healthcare
  • 7.7 Digital Health Solutions
  • 7.8 Other End Users

8 Global Infectious Disease Management Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Pfizer
  • 10.2 Gilead Sciences
  • 10.3 Johnson & Johnson
  • 10.4 Merck & Co.
  • 10.5 GlaxoSmithKline (GSK)
  • 10.6 Roche
  • 10.7 Sanofi
  • 10.8 Novartis
  • 10.9 AstraZeneca
  • 10.10 AbbVie
  • 10.11 Takeda Pharmaceutical
  • 10.12 BioNTech
  • 10.13 Moderna
  • 10.14 Eli Lilly and Company
  • 10.15 Bayer AG

List of Tables

  • Table 1 Global Infectious Disease Management Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Infectious Disease Management Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Infectious Disease Management Market Outlook, By Diagnostics (2024-2032) ($MN)
  • Table 4 Global Infectious Disease Management Market Outlook, By PCR & Molecular Diagnostics (2024-2032) ($MN)
  • Table 5 Global Infectious Disease Management Market Outlook, By Immunoassays (2024-2032) ($MN)
  • Table 6 Global Infectious Disease Management Market Outlook, By Rapid Test Kits (2024-2032) ($MN)
  • Table 7 Global Infectious Disease Management Market Outlook, By Therapeutics (2024-2032) ($MN)
  • Table 8 Global Infectious Disease Management Market Outlook, By Antibiotics (2024-2032) ($MN)
  • Table 9 Global Infectious Disease Management Market Outlook, By Antivirals (2024-2032) ($MN)
  • Table 10 Global Infectious Disease Management Market Outlook, By Antifungals (2024-2032) ($MN)
  • Table 11 Global Infectious Disease Management Market Outlook, By Antiparasitic Drugs (2024-2032) ($MN)
  • Table 12 Global Infectious Disease Management Market Outlook, By Vaccines (2024-2032) ($MN)
  • Table 13 Global Infectious Disease Management Market Outlook, By Viral Vaccines (2024-2032) ($MN)
  • Table 14 Global Infectious Disease Management Market Outlook, By Bacterial Vaccines (2024-2032) ($MN)
  • Table 15 Global Infectious Disease Management Market Outlook, By Type (2024-2032) ($MN)
  • Table 16 Global Infectious Disease Management Market Outlook, By Bacterial Infections (2024-2032) ($MN)
  • Table 17 Global Infectious Disease Management Market Outlook, By Tuberculosis (2024-2032) ($MN)
  • Table 18 Global Infectious Disease Management Market Outlook, By Pneumonia (2024-2032) ($MN)
  • Table 19 Global Infectious Disease Management Market Outlook, By Viral Infections (2024-2032) ($MN)
  • Table 20 Global Infectious Disease Management Market Outlook, By HIV/AIDS (2024-2032) ($MN)
  • Table 21 Global Infectious Disease Management Market Outlook, By Influenza (2024-2032) ($MN)
  • Table 22 Global Infectious Disease Management Market Outlook, By Hepatitis (2024-2032) ($MN)
  • Table 23 Global Infectious Disease Management Market Outlook, By COVID-19 (2024-2032) ($MN)
  • Table 24 Global Infectious Disease Management Market Outlook, By Fungal Infections (2024-2032) ($MN)
  • Table 25 Global Infectious Disease Management Market Outlook, By Parasitic Infections (2024-2032) ($MN)
  • Table 26 Global Infectious Disease Management Market Outlook, By End User (2024-2032) ($MN)
  • Table 27 Global Infectious Disease Management Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 28 Global Infectious Disease Management Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 29 Global Infectious Disease Management Market Outlook, By Ambulatory Care Centers (2024-2032) ($MN)
  • Table 30 Global Infectious Disease Management Market Outlook, By Research & Academic Institutes (2024-2032) ($MN)
  • Table 31 Global Infectious Disease Management Market Outlook, By Home Healthcare (2024-2032) ($MN)
  • Table 32 Global Infectious Disease Management Market Outlook, By Digital Health Solutions (2024-2032) ($MN)
  • Table 33 Global Infectious Disease Management Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.